# Jae‐Lyun Lee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jae-lyun-lee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,797 |
| Field | Renal cell carcinoma treatment |
| h-index | 67 |
| i10-index | 280 |
| Last Known Institution | Ulsan College |
| OpenAlex ID | https://openalex.org/A5063838757 |
| ORCID iD | https://orcid.org/0000-0002-9420-7162 |
| Works | 641 |

## Researcher papers

- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival](https://scholariq.org/papers/evaluation-of-clear-cell-papillary-and-chromophobe-renal-cell-carcinoma/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)

## Researcher university

- [Ulsan College](https://scholariq.org/institutions/ulsan-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.